Oxbryta

Active Ingredient(s): Voxelotor
FDA Approved: * November 25, 2019
Pharm Company: * GLOBAL BLOOD THERAPS
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Oxbryta Overview

Voxelotor, sold under the brand name Oxbryta, is a medication used for the treatment of sickle cell disease.[1][2][3][4][5] Developed by Global Blood Therapeutics, voxelotor is the first hemoglobin oxygen-affinity modulator.[6] Voxelotor has been shown to have disease-modifying potential by increasing hemoglobin levels and decreasing hemolysis indicators in sickle cell patients.[7] ...

Read more Oxbryta Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Voxelotor

Recent Oxbryta Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Voxelotor
  • Tablet: 500mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Oxbryta: (1 result)

Sorted by National Drug Code
  • 72786-101 Oxbryta 500 mg Oral Tablet, Film Coated by Global Blood Therapeutics Inc.

Other drugs which contain Voxelotor or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 24 October 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA